Gapping up
In reaction to strong earnings/guidance: TNK +9.9% (ticking higher), VIPS +8%, CSCO +7.2%, TSEM +6.7%, SANW +6.6%, (light volume), OPWR +4.1%, (light volume), AGYS +3.4%, (light volume), CA +3.1%, AEG +1.4% (light volume), GOL +0.5% .
M&A news: GTIV +52.2% (Gentiva Health Svcs receives proposal to be acquired by Kindred Healthcare for a combination of $7.00 per share in cash and $7.00 of Kindred common stock ), DTV +0.5% (AT&T has hired Lazard to advise on DTV buyout, according to reports).
Tech/CSCO peers trading higher: SYMC +2.8% (ValueAct disclosed stake; also following CSCO results), JNPR +1.6%, FFIV +1.5%, CIEN +1.1%, VMW +0.8%, FTNT +0.8%,
Select financial related names showing strength: HSBC +1.9%, BCS +1.4%, IBN +0.8%.
A few miners are trading higher: BBL +1.3%, RIO +1.1%, BHP +0.3%.
Biotech/drug names higher: CLVS +8.2% (confirmed clinical data to be presented at 2014 ASCO Annual Meeting; also mentioned by Adam Feuerstein -- highlights lung cancer related names ), MNTA +4.7% (on TEVA Copaxone news), ISIS +4.5% (ISIS Pharm earns a $3.0 mln milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study), XNPT +3.7% (Xenoport and Reckitt Benckiser Pharmaceuticals Enter Into Global Licensing Agreement for Arbaclofen Placarbil), CLDX +1.7% (announces Varlilumab (CDX-1127) Phase 1 clinical data to be presented at ASCO Annual Meeting 2014), MYL +1.6% (comments on ruling against Teva in their suit against the FDA, which denied Teva's motion to block FDA from approving generic versions of Copaxone and dismissed the case for lack of jurisdiction).
Select China internet names getting boost following VIPS results: WUBA +1%, YY +0.7%, QIHU +0.7%, SINA +0.5%, VNET +0.3%
Other news: NWBO +17.8% (announces first data from ongoing DCVAX-Direct trial; evidence indicates substantial tumor necrosis and initial tumor regression), DRL +10.9% (calls on the Puerto Rico government to honor its obligations), AMED +3.6% (following GTIV news), DQ +2.8% (modestly rebounding), WILN +2.2% (concludes strategic review, formulates growth plan; to increase dividend 25%), DNDN +1.9% (announces presentation of PROVENGE and DN24-02 immuno-oncology data at the 2014 ASCO annual meeting), RATE +1.6% (following CEO insider buy), JDSU +1.5% (following A results), DQ +1.4% (prices 2 mln ADSs at $29.00 per share ), WWE +1.3% (following late move higher on tv contract speculation), UL +0.9% (still checking), HFC +0.8% (announces increase in regular dividend by 6.6% to $0.32 per share and declares additional $0.50 special dividend), BDBD +0.8% (positive MadMoney mention), MUR +0.3% ( announces additional $125 mln share repurchase program; also may sell Malaysia oil and gas assets for $ 2 bln, according to reports ), EXPD +0.2% (ValueAct discloses updated portfolio positions in 13F filing).
Analyst comments: NMBL +7.8% (upgraded to Buy from Neutral at Goldman; tgt lowered to $34 from $46), PLUG +6% (upgraded to Outperform from Mkt Perform at Cowen; tgt lowered to $6 from $7.50), MILL +2.3% (assumed with a Buy (from hold) at Brean Capital), KMI +1.9% (added to Conviction Buy list at Goldman), TWTR +1.1% ( upgraded to Neutral from Underweight at Atlantic Equities), SRC +1% (upgraded to Buy from Neutral at Ladenburg Thalmann)
M&A news: GTIV +52.2% (Gentiva Health Svcs receives proposal to be acquired by Kindred Healthcare for a combination of $7.00 per share in cash and $7.00 of Kindred common stock ), DTV +0.5% (AT&T has hired Lazard to advise on DTV buyout, according to reports).
Tech/CSCO peers trading higher: SYMC +2.8% (ValueAct disclosed stake; also following CSCO results), JNPR +1.6%, FFIV +1.5%, CIEN +1.1%, VMW +0.8%, FTNT +0.8%,
Select financial related names showing strength: HSBC +1.9%, BCS +1.4%, IBN +0.8%.
A few miners are trading higher: BBL +1.3%, RIO +1.1%, BHP +0.3%.
Biotech/drug names higher: CLVS +8.2% (confirmed clinical data to be presented at 2014 ASCO Annual Meeting; also mentioned by Adam Feuerstein -- highlights lung cancer related names ), MNTA +4.7% (on TEVA Copaxone news), ISIS +4.5% (ISIS Pharm earns a $3.0 mln milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study), XNPT +3.7% (Xenoport and Reckitt Benckiser Pharmaceuticals Enter Into Global Licensing Agreement for Arbaclofen Placarbil), CLDX +1.7% (announces Varlilumab (CDX-1127) Phase 1 clinical data to be presented at ASCO Annual Meeting 2014), MYL +1.6% (comments on ruling against Teva in their suit against the FDA, which denied Teva's motion to block FDA from approving generic versions of Copaxone and dismissed the case for lack of jurisdiction).
Select China internet names getting boost following VIPS results: WUBA +1%, YY +0.7%, QIHU +0.7%, SINA +0.5%, VNET +0.3%
Other news: NWBO +17.8% (announces first data from ongoing DCVAX-Direct trial; evidence indicates substantial tumor necrosis and initial tumor regression), DRL +10.9% (calls on the Puerto Rico government to honor its obligations), AMED +3.6% (following GTIV news), DQ +2.8% (modestly rebounding), WILN +2.2% (concludes strategic review, formulates growth plan; to increase dividend 25%), DNDN +1.9% (announces presentation of PROVENGE and DN24-02 immuno-oncology data at the 2014 ASCO annual meeting), RATE +1.6% (following CEO insider buy), JDSU +1.5% (following A results), DQ +1.4% (prices 2 mln ADSs at $29.00 per share ), WWE +1.3% (following late move higher on tv contract speculation), UL +0.9% (still checking), HFC +0.8% (announces increase in regular dividend by 6.6% to $0.32 per share and declares additional $0.50 special dividend), BDBD +0.8% (positive MadMoney mention), MUR +0.3% ( announces additional $125 mln share repurchase program; also may sell Malaysia oil and gas assets for $ 2 bln, according to reports ), EXPD +0.2% (ValueAct discloses updated portfolio positions in 13F filing).
Analyst comments: NMBL +7.8% (upgraded to Buy from Neutral at Goldman; tgt lowered to $34 from $46), PLUG +6% (upgraded to Outperform from Mkt Perform at Cowen; tgt lowered to $6 from $7.50), MILL +2.3% (assumed with a Buy (from hold) at Brean Capital), KMI +1.9% (added to Conviction Buy list at Goldman), TWTR +1.1% ( upgraded to Neutral from Underweight at Atlantic Equities), SRC +1% (upgraded to Buy from Neutral at Ladenburg Thalmann)